Drug Screening Using Novel IMD in Renal Cell Carcinoma (NCT05700461)

🧪 Interventions in This Study

• Implantable Microdevice (IMD) (COMBINATION_PRODUCT)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Patients must have the ability to understand and the willingness to sign a written informed consent document.
2. Participants must have confirmed or suspected localized or metastatic renal cell carcinoma, and must be planned for either nephrectomy or metastatectomy as part of their clinical care. The lesion planned for excision must be at least 1cm in size.
3. Participants must be 18 years of age or older.
4. Participants must be evaluated by a medical oncologist who will determine the clinically appropriate treatment strategy based on clinical history and extent of disease.
5. Patients must be deemed medically stable to undergo both percutaneous procedures and standard-of-care surgical procedures.
6. Participants will undergo laboratory testing within 30 days prior to the procedure (or within 72 hours if there has been a change in the clinical status since the initial blood draw). Patients must have absolute neutrophil count ≥1,000/mcL, platelets ≥50,000/mcL, INR \< 1.5 and PTT \<1.5x control.
7. Participants must have undergone CT or MRI that assesses the extent of disease and allows the research team to assess for study eligibility. This will have been done as part of the standard-of-care.
8. The participant's case must be reviewed by representatives of interventional radiology and the appropriate surgical subspecialty to assess the following factors:
9. Patient is clinically stable to undergo microdevice implantation and surgical procedures
10. Patient has sufficient volume of disease to allow implantation of the microdevice
11. Patient has a lesion for which the microdevice is a) amenable to percutaneous placement, and b) amenable to removal at the time of surgery
12. Patients must be willing to undergo research-related genetic sequencing (somatic and germline) and data management, including the deposition of de-identified genetic sequencing data in NIH central data repositories.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

• Dana-Farber Cancer Institute — Boston, Massachusetts

📞 Contact the Study Coordinator

Phone: (617) 632-6534

Email: Wenxin_Xu1@dfci.harvard.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Renal Cell Carcinoma

• Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations — Baltimore, Maryland
• Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC) — Birmingham, Alabama
• Delving Into Participation Trends in Renal Cell Carcinoma Studies — San Francisco, California
• A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma — Birmingham, Alabama
• A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma — Basking Ridge, New Jersey

Explore by condition: All Renal Cell Carcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.